Conference
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects
Abstract
Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated high activity in renal cell carcinoma (RCC) and is now widely used for patients with metastatic disease. Although generally well tolerated and associated with a low incidence of common toxicity criteria grade 3 or 4 toxicities, sunitinib exhibits a distinct pattern of novel side effects that require monitoring and management. This article summarizes the …
Authors
Kollmannsberger C; Soulieres D; Wong R; Scalera A; Gaspo R; Bjarnason G
Volume
1
Pagination
pp. s41-s54
Publisher
Canadian Urological Association Journal
Publication Date
June 2007
DOI
10.5489/cuaj.67
Conference proceedings
Canadian Urological Association Journal
Issue
2S
ISSN
1911-6470